737. Implementation of Antibiotic stewardship : A South Indian experience
Session: Poster Abstract Session: Stewardship: Program Implementation
Thursday, October 5, 2017
Room: Poster Hall CD
  • ASP poster final 28-9.pdf (382.1 kB)


    Background: Access to antimicrobials in India is unregulated. Retail data confirms antibiotic prescriptions have escalated in the last decade, contributing to antimicrobial resistance. Antimicrobial stewardship programs (ASP) are rare in India but, with government support, are gaining momentums. We describe implementation of an ASP in a 1300-bed, private, tertiary-care center in India in Southern India.

    Methods: An ASP was established in Feb 2016 consisting of an administrative champion, hospitalist, microbiologist, intensivist and 5 pharmacists. Daily post-prescriptive review of targeted antimicrobials was done, including polymyxins, carbapenems, tigecycline, and linezolid. Institutional guidelines for polymyxins were created and disseminated. Socioadaptive strategies included promoting culture change & empowering pharmacist champions. The ASP evaluated & tracked the appropriateness of antimicrobial administration, including loading and maintenance dose, frequency, route, duration of therapy, de-escalation & compliance with ASP recommendations. Economic impact of ASP post implementation (Feb – July 2016) was compared with a pre-implementation period (Aug 2015 - Jan 2016).

    Results: In the post implementation period, 868 patients were prescribed targeted antibiotics. 51% (442) prescriptions required adjustment for drug selection, route, dose, or duration. Loading dose was indicated but not prescribed in 31% (266) of prescriptions, 14% (118) had inappropriate maintenance dose & 13% (110) were continued beyond standard recommended durations. Compliance was noted with 50% of ASP recommendations. Departments with high compliance rates included Neurosurgery (63%), Urology (62%), and Medicine (59%). Significant decreases in cost (Fig 1) were noted for ertapenem (Rs 106200 reduced to Rs 15930), colistin (Rs 1368258 to Rs 338322) and linezolid (Rs 919296 to Rs 137472) (all p < 0.05) ( 1USD~64 Rs). Utilization of Colistin and Linezolid decreased from 422 vials to 94 (22%) and 1320 vials to 202 (15%), respectively.

    Conclusion: Preliminary results of an ASP in a large Indian hospital are encouraging. Potential antibiotic and department-specific targets for advanced stewardship interventions were identified.














    Sanjeev Singh, DCH, MD, PhD1, Vidya Menon, MD, FACP2, Anil Kumar, MBBS, MD3, Vrinda Nampoothiri, PharmD3, Zubair Umer Mohamed, MD, FRCA, FCARCSI, EDIC, FFICM, CCT3, Sangita Sudhir, PharmD3, Jason Pogue, PharmD4, Keith S. Kaye, MD, MPH5 and Payal Patel, MD, MPH6, (1)Medical Administration, Amrita Institute of Medical Sciences, Kochi, India, (2)General Medicine, Amrita Institute of Medical Sciences and Research Centre, Kochi, India, (3)Amrita Institute of Medical Sciences and Research Centre, Kochi, India, (4)Detroit Medical Center/Wayne State University, Detroit, MI, (5)Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, (6)University of Michigan, Ann Arbor, MI


    S. Singh, None

    V. Menon, None

    A. Kumar, None

    V. Nampoothiri, None

    Z. U. Mohamed, None

    S. Sudhir, None

    J. Pogue, None

    K. S. Kaye, Xellia: Consultant , Consulting fee
    Merck: Consultant and Grant Investigator , Consulting fee and Research support
    The Medicines Company: Consultant and Grant Investigator , Consulting fee and Research support

    P. Patel, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.